Information on EC 3.4.21.68 - t-Plasminogen activator

Word Map on EC 3.4.21.68
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota, Bacteria

EC NUMBER
COMMENTARY hide
3.4.21.68
-
RECOMMENDED NAME
GeneOntology No.
t-Plasminogen activator
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
Specific cleavage of Arg-/-Val bond in plasminogen to form plasmin
show the reaction diagram
specific cleavage of Arg-+-Val, the term -+- depicts the point of cleavage
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hydrolysis of peptide bond
CAS REGISTRY NUMBER
COMMENTARY hide
139639-23-9
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
no activity in Cucumis melo
cv. Geumssaragi-euncheon, hairy roots
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
metabolism
-
tissue-type plasminogen activator functions as the main activator of the fibrinolytic process in the intravascular compartment
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(p-F)-FPRANSNH-C2H5 + H2O
(p-F)-FPR + ANSNH-C2H5
show the reaction diagram
-
-
-
?
Asp-Gly-Arg-p-nitroanilide + H2O
Asp-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-Asp(O-tert-butyl)-Gly-Arg-p-nitroanilide + H2O
benzyloxycarbonyl-Asp(O-tert-butyl)-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-Asp-Gly-Arg-p-nitroanilide + H2O
benzyloxycarbonyl-Asp-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-D-Asp(O-tert-butyl)-Gly-Arg-p-nitroanilide + H2O
benzyloxycarbonyl-D-Asp(O-tert-butyl)-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-D-Glu(O-tert-butyl)-Gly-Arg-p-nitroanilide + H2O
benzyloxycarbonyl-D-Glu-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-D-Glu-Gly-Arg-p-nitroanilide + H2O
benzyloxycarbonyl-D-Glu-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-D-Phe-Gly-Arg-p-nitroanilide + H2O
benzyloxycarbonyl-D-Phe-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-Glu(O-tert-butyl)-Gly-Arg-p-nitroanilide + H2O
benzyloxycarbonyl-Glu(O-tert-butyl)-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-pyroglutamic acid-Gly-Arg-p-nitroanilide + H2O
benzyloxycarbonyl-pyroglutamic acid-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-Val-Gly-Arg-p-nitroanilide + H2O
benzyloxycarbonyl-Val-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
Boc-(p-F)-FPRANSNH-C2H5 + H2O
Boc-(p-F)-FPR + ANSNH-C2H5
show the reaction diagram
-
-
-
?
Boc-D-FLRANSNH-C3H7 + H2O
Boc-D-FLR + ANSNH-C3H7
show the reaction diagram
-
-
-
?
Boc-D-FPRANSNH-C6H11 + H2O
Boc-D-FPR + ANSNH-C6H11
show the reaction diagram
-
-
-
?
Boc-D-FVRANSNH-C2H5 + H2O
Boc-D-FVR + ANSNH-C2H5
show the reaction diagram
-
-
-
?
Boc-D-LGRANSNH-C6H11 + H2O
Boc-D-LGR + ANSNH-C6H11
show the reaction diagram
-
-
-
?
Boc-D-LPRANSNH-C3H7 + H2O
Boc-D-LPR + ANSNH-C3H7
show the reaction diagram
-
-
-
?
Boc-D-LSRANSNH-C3H7 + H2O
Boc-D-LSR + ANSNH-C3H7
show the reaction diagram
-
-
-
?
Boc-D-VGRANSNH-C4H9 + H2O
Boc-D-VGR + ANSNH-C4H9
show the reaction diagram
-
-
-
?
Boc-D-VPRANSNH-C4H9 + H2O
Boc-D-VPR + ANSNH-C4H9
show the reaction diagram
-
-
-
?
Boc-L-FPRANSNH-C2H5 + H2O
Boc-L-FPR + ANSNH-C2H5
show the reaction diagram
-
-
-
?
Boc-L-VGRANSNH-C4H9 + H2O
Boc-L-VGR + ANSNH-C4H9
show the reaction diagram
-
-
-
?
casein + H2O
?
show the reaction diagram
cyclohexylglycyl-Gly-Arg-p-nitroanilide + H2O
cyclohexylglycyl-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
D-Asp-Gly-Arg-p-nitroanilide + H2O
D-Asp-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
D-cyclohexylglycyl-Gly-Arg-p-nitroanilide + H2O
D-cyclohexylglycyl-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
D-FLRANSNH-C3H7 + H2O
D-FLR + ANSNH-C3H7
show the reaction diagram
-
-
-
?
D-FPR ANSNH-C6H11 + H2O
D-FPR + ANSNH-C6H11
show the reaction diagram
-
-
-
?
D-FPRANSN-(CH2)6 + H2O
D-FPR + ANSN-(CH2)6
show the reaction diagram
-
-
-
?
D-FPRANSN-C2H5 + H2O
D-FPR + ANSN-C2H5
show the reaction diagram
-
-
-
?
D-FPRANSNH-c-C6H11 + H2O
D-FPR + ANSNH-c-C6H11
show the reaction diagram
-
-
-
?
D-FPRANSNH-C2H4OCH3 + H2O
D-FPR + ANSNH-C2H4OCH3
show the reaction diagram
-
-
-
?
D-FPRANSNH-C6H5CH2 + H2O
D-FPR + ANSNH-C6H5CH2
show the reaction diagram
-
-
-
?
D-FPRANSNH-CH2COOCH3 + H2O
D-FPR + ANSNH-CH2COOCH3
show the reaction diagram
-
-
-
?
D-FPRANSNH-i-C3H7 + H2O
D-FPR + ANSNH-i-C3H7
show the reaction diagram
-
-
-
?
D-FPRANSNH-n-C4H9 + H2O
D-FPR + ANSNH-n-C4H9
show the reaction diagram
-
-
-
?
D-FPRANSNH-n-C6H13 + H2O
D-FPR + ANSN-H-n-C6H13
show the reaction diagram
-
-
-
?
D-FPRANSNH-t-C4H9 + H2O
D-FPR + ANSNH-t-C4H9
show the reaction diagram
-
-
-
?
D-FVRANSNH-C2H5 + H2O
D-FVR + ANSNH-C2H5
show the reaction diagram
-
-
-
?
D-Glu-Gly-Arg-p-nitroanilide + H2O
D-Glu-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
D-Glu-Phe-Lys-p-nitroanilide + H2O
D-Glu-Phe-Lys + p-nitroaniline
show the reaction diagram
-
-
-
-
-
D-hexahydrotyrosyl-Gly-Arg-p-nitroanilide + H2O
D-hexahydrotyrosyl-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
D-Ile-Pro-Arg-4-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
D-Ile-Pro-Arg-p-nitroanilide + H2O
D-Ile-Pro-Arg + p-nitroaniline
show the reaction diagram
-
-
-
-
?
D-LGRANSNH-C6H11 + H2O
D-LGR + ANSNH-C6H11
show the reaction diagram
-
-
-
?
D-LPRANSNH-C3H7 + H2O
D-LPR + ANSNH-C3H7
show the reaction diagram
-
-
-
?
D-LSRANSNH-C3H7 + H2O
D-LSR + ANSNH-C3H7
show the reaction diagram
-
-
-
?
D-Lys-Gly-Arg-p-nitroanilide + H2O
D-Lys-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
D-norleucyl-hexahydrotyrosol-lysine-p-nitroanilide + H2O
D-norleucyl-hexahydrotyrosol-lysine + p-nitroaniline
show the reaction diagram
-
-
-
-
?
D-Phe-Gly-Arg-p-nitroanilide + H2O
D-Phe-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
D-Val-L-Leu-L-Lys-p-nitroanilide + H2O
D-Val-L-Leu-L-Lys + p-nitroaniline
show the reaction diagram
-
-
-
-
?
D-Val-Leu-Lys-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
D-Val-Leu-Lys-p-nitroanilide + H2O
D-Val-Leu-Lys + p-nitroanilide
show the reaction diagram
-
-
-
-
?
D-Val-Leu-Lys-p-nitroanilide + H2O
D-Val-Leu-Lys + p-nitroaniline
show the reaction diagram
-
-
-
-
?
D-valyl-L-leucyl-L-lysine 4-nitroanilide + H2O
D-valyl-L-leucyl-L-lysine + 4-nitroaniline
show the reaction diagram
-
-
-
-
?
D-VGRANSNH-C4H9 + H2O
D-VGR + ANSNH-C4H9
show the reaction diagram
-
-
-
?
D-VPRANSNH-C4H9 + H2O
D-VPR + ANSNH-C4H9
show the reaction diagram
-
-
-
?
di-Glu-Pro-Arg-4-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
Glu-Gly-Arg-p-nitroanilide + H2O
Glu-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
Glu-plasminogen + H2O
plasmin + ?
show the reaction diagram
-
-
-
-
?
glutaryl-Gly-7-Arg-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
L-VGRANSNH-C4H9 + H2O
L-VGR + ANSNH-C4H9
show the reaction diagram
-
-
-
?
Laminin + H2O
?
show the reaction diagram
-
tPA amplifies excitotoxic neuronal death by degrading laminin and disruption of pro-survival cell-matrix signaling
-
-
?
Lys-Lys-Cys-Pro-Gly-Arg-Val-Val-Gly-Gly-Cys-Val-Ala-His + H2O
?
show the reaction diagram
-
-
-
-
-
Lys-Lys-Ser-Pro-Gly-Arg-Val-Val-Gly-Gly-Ser-Val-Ala-His + H2O
?
show the reaction diagram
-
-
-
-
-
Lys-plasminogen + H2O
plasmin + ?
show the reaction diagram
-
-
-
?
methyloxycarbonyl-D-cyclohexylalanyl-Gly-Arg-p-nitroanilide + H2O
methyloxycarbonyl-D-cyclohexylglycyl-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
methyloxycarbonyl-D-cyclohexylglycyl-Gly-Arg-p-nitroanilide + H2O
methyloxycarbonyl-D-cyclohexylglycyl-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
methyloxycarbonyl-D-hexahydrotyrosyl-Gly-Arg-p-nitroanilide + H2O
methyloxycarbonyl-D-hexahydrotyrosyl-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
methyloxycarbonyl-D-Leu-Gly-Arg-p-nitroanilide + H2O
methyloxycarbonyl-D-Leu-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
methyloxycarbonyl-D-Nle-Gly-Arg-p-nitroanilide + H2O
methyloxycarbonyl-D-Nle-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
methyloxycarbonyl-D-Val-Gly-Arg-p-nitroanilide + H2O
methyloxycarbonyl-D-Nle-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
methylsulfonyl-D-cyclohexylglycyl-Arg-7-amido-4-methylcoumarin + H2O
methylsulfonyl-D-cyclohexylglycyl-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine-p-nitroanilide + H2O
methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine + p-nitroaniline
show the reaction diagram
-
a chromogenic substrate
-
-
?
methylsulfonyl-D-Phe-Gly-Arg-7-amido-4-methylcoumarin + H2O
methylsulfonyl-D-Phe-Gly-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide + H2O
methylsulfonyl-D-Phe-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
MMP-9 + H2O
?
show the reaction diagram
-
tPA directly or by activation of MMP-9, can have beneficial effects on recovery after stroke by promoting neurovascular repair through vascular endothelial growth factor
-
-
?
N-methyl-D-aspartate receptor + H2O
?
show the reaction diagram
-
usage of total rat brain lysates or MBP-ATD2B fusion proteins, the recombinant human enzyme shows cleavage of the ATD sequence in the NR2B subunit N-terminus of N-methyl-D-aspartate (NMDA) receptor. Enzyme-mediated degradation of NR2B is plasmin-independent. The enzyme cleaves the MBP-ATD2B fusion protein
an Arg27-Arg67-truncated NR2B-containing NMDA receptor might be formed
-
?
N-methyl-D-aspartate receptor NR1 subunit + H2O
?
show the reaction diagram
PAR-1 + H2O
?
show the reaction diagram
-
toxic effects of tPA in stroke can be mediated through activation of PAR-1
-
-
?
Peptide S-2288 + H2O
?
show the reaction diagram
-
chromogenic substrate
-
-
-
Phe-Gly-Arg-p-nitroanilide + H2O
Phe-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
plasmin + H2O
?
show the reaction diagram
-
-
-
-
?
plasminogen + H2O
?
show the reaction diagram
plasminogen + H2O
plasmin + ?
show the reaction diagram
plasminogen + H2O
plasminon + ?
show the reaction diagram
-
-
-
-
?
Plasminogen-activator-inhibitor 1 + H2O
?
show the reaction diagram
platelet-derived growth factor C + H2O
?
show the reaction diagram
-
-
-
?
S-2288TM + H2O
?
show the reaction diagram
-
amidolytic activity of recombinant tPA bound to polyacrylic acid-coated magnetite is 87% of that of free recombinant tPA. Amidolytic activity of recombinant tPA immobilized on magnetic nanoparticles coated with dextran is only 11-24% of recombinant tPA bound to polyacrylic acid-coated magnetite
-
-
?
SNase PFGRSA + H2O
SNase-PFGR + Ser-Ala
show the reaction diagram
-
staphylococcal nuclease with substitutions for amino acids 44-51
-
?
SNase PFGRSAG + H2O
SNase-PFGR + Ser-Ala-Gly
show the reaction diagram
-
staphylococcal nuclease with substitutions for amino acids 44-51
-
?
SNase PGPFGRSAG + H2O
SNase-PGPFGR + Ser-Ala-Gly
show the reaction diagram
-
staphylococcal nuclease with substitutions for amino acids 44-51
-
?
SNase PGPFGRSAGG + H2O
SNase-PGPFGR + Ser-Ala-Gly-Gly
show the reaction diagram
-
staphylococcal nuclease with substitutions for amino acids 44-51
-
?
SNase PGSGRSAG + H2O
SNase-PGSGR + Ser-Ala-Gly
show the reaction diagram
-
staphylococcal nuclease with substitutions for amino acids 44-51
-
?
SNase PHYGRSGG + H2O
SNase-PHYGR + Ser-Gly-Gly
show the reaction diagram
-
staphylococcal nuclease with substitutions for amino acids 44-51
-
?
SNase PPFGRSAG + H2O
SNase-PPFGR + Ser-Ala-Gly
show the reaction diagram
-
staphylococcal nuclease with substitutions for amino acids 44-51
-
?
SNase PQRGRSAG + H2O
SNase-PQRGR + Ser-Ala-Gly
show the reaction diagram
-
staphylococcal nuclease with substitutions for amino acids 44-51
-
?
spectrozyme tPA + H2O
?
show the reaction diagram
-
-
-
?
tert-butyloxycarbonyl-Gly-Gly-Arg-p-nitroanilide + H2O
tert-butyloxycarbonyl-Gly-Gly-Arg + p-nitroaniline
show the reaction diagram
-
-
-
?
thrombin + H2O
?
show the reaction diagram
-
-
-
-
?
Val-Leu-Lys-p-nitroanilide + H2O
p-nitroaniline + ?
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
N-methyl-D-aspartate receptor NR1 subunit + H2O
?
show the reaction diagram
plasminogen + H2O
?
show the reaction diagram
plasminogen + H2O
plasmin + ?
show the reaction diagram
plasminogen + H2O
plasminon + ?
show the reaction diagram
-
-
-
-
?
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
additional information
-
native and recombinant beta2-glycoprotein I or its domain V stimulate tPA-dependent plasminogen activation in a concentration-dependent manner. Beta2-glycoprotein I binds tPA with high affinity (Kd =20 nmol), stimulates tPA amidolytic activity, and causes an overall 20fold increase in the catalytic efficiency (kcat/Km) of tPA-mediated conversion of Glu-plasminogen to plasmin
-
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1,5-Dansyl-L-glutamylglycyl-L-arginine chloromethyl ketone
-
-
2,5-Bis(4-amidinobenzylidene)cyclopentanone
-
-
2,6-Bis(4-amidinobenzylidene)cyclohexanone
-
-
2,7-Bis(4-amidinobenzylidene)cycloheptanone
-
-
2,7-bis-(4-amidinobenzylidene)-cycloheptanone-(1)dihydrochloride
2,8-Bis(4-amidinobenzylidene)cyclooctanone
-
-
2-([6-[(3'-carbamimidoylbiphenyl-3-yl)oxy]-3,5-difluoro-4-methylpyridin-2-yl]oxy)-4-(dimethylamino)benzoic acid
-
-
2-[(6-[[3'-(aminomethyl)biphenyl-3-yl]oxy]-3,5-difluoropyridin-2-yl)oxy]-4-methylbenzoic acid
-
-
2-[(6-[[5-amino-3'-(aminomethyl)biphenyl-3-yl]oxy]-3,5-difluoropyridin-2-yl)oxy]-4-methylbenzoic acid
-
-
4-(2-aminoethoxy)-N-[3-chloro-2-ethoxy-5-(piperidin-1-yl)phenyl]-3,5-dimethylbenzamide
-
-
4-[(E)-(5-oxo-2-phenyl-1,3-oxazol-4(5H)-ylidene)methyl]benzenecarboximidamide
-
-
6-carbamimidoyl-N-(3,5-dimethoxyphenyl)-2-naphthamide
-
-
6-carbamimidoyl-N-phenyl-2-naphthamide
-
-
6-methoxy-N-(3'-(trifluoromethyl)biphenyl-4-yl)-2-naphthamide
-
-
6-methoxy-N-(3'-(trifluoromethyl)biphenyl-4-yl)naphthalene-2-sulfonamide
-
-
6-methoxy-N-(3'-methoxybiphenyl-4-yl)-2-naphthamide
-
-
6-methoxy-N-(3'-nitrobiphenyl-4-yl)-2-naphthamide
-
-
AEBSF
-
protease inhibitor
alpha-1-Proteinase inhibitor
-
-
-
alpha-2-Antiplasmin
-
-
-
alpha-2-Macroglobulin
-
-
-
alpha2-antiplasmin
-
-
-
Aprotinin
benzamidine
-
-
bis[(phenylamino)acetyl] [2-(4-carbamimidamidophenyl)-1-[(methoxycarbonyl)amino]ethyl]phosphonate
-
-
bivalirudin
-
does not exert any protective effect when added at concentrations of 20-200 microg/ml (cell viability of 51.8%)
C1-inhibitor
-
-
-
Cd2+
-
inhibition of amidolytic activity
Cell/platelet-type plasminogen activator inhibitor
-
from bovine aortic endothelial
-
Co2+
-
inhibition of amidolytic activity
Cu2+
-
inhibition of amidolytic activity
diphenyl [2-(4-carbamimidamidophenyl)-1-[(methoxycarbonyl)amino]ethyl]phosphonate
-
-
epsilon-aminocaproic acid
ethyl 4-(3-carbamimidoyl-N-[[2,4,6-tri(propan-2-yl)phenyl]sulfonyl]-L-phenylalanyl)piperazine-1-carboxylate
-
-
Fast-acting plasminogen activator inhibitor in plasma
-
-
-
Gabexate
-
-
Glu-Gly-Arg-chlormethylketone
-
directly binds to the catalytic site of tPA. 100 microg/ml given before tPA exposure, reduces cell death (cell viability of 80.5%)
H89
-
inhibits dibutyryl-cAMP-mediated changes in tPA activity without affecting metalloproteinase-9 activity
Hg2+
-
inhibition of amidolytic activity
Human plasminogen activator inhibitors
-
leupeptin
lipopolysaccharide
-
decreases tPA activity. Co-treatment with dibutyryl-cAMP and lipopolysaccharide dose-dependently prevents lipopolysaccharide-induced downregulation of tPA activity
mesilate
-
-
methyl 4'-(6-carbamoyl-2-naphthamido)biphenyl-3-carboxylate
-
-
methyl 4'-(6-methoxy-2-naphthamido)biphenyl-3-carboxylate
-
-
methyl 4'-(6-methoxynaphthalene-2-sulfonamido)biphenyl-3-carboxylate
-
-
Myxoma virus serine proteinase inhibitor
-
-
-
N-((2-(iodoacetoxy)ethyl)-N-methyl)amino-7-nitrobenz-2-oxa-3-diazole
-
P9 plasminogen activator inhibitor-1
N-(4-(aminomethyl)phenyl)-6-carbamimidoyl-2-naphthamide trifluoro acetate
-
-
N-(benzylsulfonyl)-D-seryl-N-(4-carbamimidoylbenzyl)-L-alaninamide
-
-
N2-(2,4'-dimethoxybiphenyl-4-yl)naphthalene-2,6-dicarboxamide
-
-
N2-(3'-(trifluoromethyl)biphenyl-4-yl)naphthalene-2,6-dicarboxamide
-
-
N2-(3'-methoxybiphenyl-4-yl)naphthalene-2,6-dicarboxamide
-
-
NaCl
-
high concentrations inhibit the binding of beta2-glycoprotein I to tPA
neuroserpin
-
endogenous inhibitor, regulating tPA activity
-
Ni2+
-
inhibition of amidolytic activity
p-aminobenzamidine
-
-
PAI-1
-
ethanol can downregulate the expression of PAI-1, a main inhibitor of tPA in the CNS
-
PAI-1 inhibitor
-
-
-
Phe-Pro-Arg-chlormethylketone
-
directly binds to the catalytic site of tPA. 100 microg/ml given before tPA exposure, reduces cell death (cell viability of 85.7%)
Placental-type plasminogen activator inhibitor
-
-
-
plasminogen
-
substrate inhibition, at low concentrations of t-PA and D-dimer of fibrin containing the D-domain of fibrin in the presence of physiological concentrations of plasminogen
-
plasminogen activator inhibitor
-
PAI-1
-
plasminogen activator inhibitor 1
plasminogen activator inhibitor PAI-1
-
-
-
plasminogen activator inhibitor PAI-2
-
-
-
plasminogen activator inhibitor type 1
-
plasminogen activator inhibitor type 1 (PAI-1)
-
plasminogen activator inhibitor type 2
-
can inhibit cell-bound tPA activity in vitro and thus prevents plasmin formation. Plasminogen activator inhibitor type 2 prevents annexin II heterotetramer/tPA-mediated plasminogen activation by its classic serpin inhibitory activity rather than through competition with tPA/plasminogen for binding. It inhibits cell bound tPA-induced plasmin activity in both an annexin II heterotetramer-dependent and -independent manner
-
plasminogen activator inhibitor type-1
-
major inhibitor of tissue-type plasminogen activator in the blood
-
plasminogen activator inhibitor-1
plasminogen activator inhibitor-1 (PAI-1)
-
; sctPA is more susceptible to PAI-1 in buffer solution and in the presence of fibrinogen. In the presence of fibrin there is no difference between single-chain enzyme tPA (sctPA) and two chain tPA (tctPA)
-
plasminogen activator inhibitor-I
-
rapidly inactivates the catalytic activity of tPA in the blood stream
-
propanolol
-
in normotensive subjects, t-PA release by epinephrine is abolished in the presence of propanolol (10 microg/100 ml per minute). In essential hypertensive patients, the response to isoproterenol is impaired as compared with normotensive subjects and is unaffected by NG-monomethyl-L-arginine coinfusion
Protease nexin-like plasminogen activator inhibitor
-
-
-
Rp-cAMP
-
inhibits dibutyryl-cAMP-mediated changes in tPA activity without affecting metalloproteinase-9 activity
serpin plasminogen activator inhibitor (PAI)-1
-
primary physiological inhibitor
-
tPA-STOP
-
a synthetic specific inhibitor to tissue plasminogen activator
transforming growth factor-beta1
-
partially inhibits interleukin-1alpha induced expression of tPA mRNA in a dose-dependent manner, maximal inhibition at 60 ng/ml
-
xenon
Zn2+
-
inhibition of amidolytic activity
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
adenosine
-
potentiates mast cell tPA activity and tPA gene expression, abolished in the presence of adenosine deaminase
bradykinin
-
endothelium-dependent vasodilator that stimulates the release of t-PA. Causes a dose-dependent increase in plasma t-PA antigen and activity concentrations in the infused arm of both pregnant and non-pregnant women. The increase in t-PA activity is greater in the nonpregnant women. Bradykinin increases the net release of t-PA antigen and activity in both pregnant women and non-pregnant women. Both net release of active t-PA and plasma t-PA/plasminogen activator inhibitor type 1 ratios are markedly reduced in pregnant women
cyanogen bromide fibrinogen digest (FIBGN)
-
FIBGN is required for the detection of tPA activity chromogenically
-
cyanogen bromide-treated fibrinogen (CNBr-Fbg)
-
CNBr-Fbg (50 microgram/ml) give a 10-fold enhancement of activation, and addition of 2.86 microg/ml oversulfated chondroitin-6-sulfate or oversulfated fucoidan amplified this to 15-fold. A 25-fold to 35-fold enhancement of activation of glutamic plasminogen by tPA is obtained when 2.86 microgram/ml oversulfated compounds are combined with 16.2 mmol/l lysine and 50 microgram/ml CNBr-Fbg
-
dibutyryl-cAMP
-
slightly increases level of tPA mRNA expression. Concentration-dependently increases tPA activity in both basal and lipopolysaccharide-stimulated rat primary astrocytes. Treatment with 100 micromol increases tPA activity by 757.9% compared with lipopolysaccharide treatment. Differentially modulates MMP-9 and tPA activity through a mechanism related to PKA activation. Co-treatment with lipopolysaccharide and dibutyryl-cAMP does not have an additive effect on tPA mRNA induction
epinephrine
-
intrabrachial infusion of epinephrine (0.1 to 0.3 microg/100 ml per minute) induces greater t-PA release in normotensive subjects as compared with essential hypertensive patients
Fibrin
fibrinogen
-
IBMX
-
increases tPA activity in lipopolysaccharide-stimulated rat primary astrocytes
interleukin-1alpha
-
increases mRNA and protein expression of tPA in a time- and dose-dependent manner. Maximal stimulation at 72 h and 100 U/ml
-
isoproterenol
-
intrabrachial isoproterenol (0.03 mcirog/100 ml per minute) induces a significant increase in t-PA release, an effect blunted by NG-monomethyl-L-arginine
L-lysine
-
addition of 16.2 mmol/l L-lysine give 3fold to 4fold enhancement of activation, which is further enhanced to 5fold to 6fold by addition of 2.86 microgram/ml oversulfated chondroitin-6-sulfate or oversulfated fucoidan
lipopolysaccharide
-
slightly increases level of tPA mRNA expression. Co-treatment with lipopolysaccharide and dibutyryl-cAMP does not have an additive effect on tPA mRNA induction
melanotransferrin
-
-
-
oversulfated chondroitin-6-sulfate
-
addition of 28.6 microgram/ml gives 2-fold to 4-fold increase in the rate of enhancement of activation of glutamic plasminogen by tPA using 0.05 mol/l Tris buffer (pH 7.35) containing NaCl (0.9%)
-
oversulfated fucoidan
-
addition of 28.6 microgram/ml gives 2-fold to 4-fold increase in the rate of enhancement of activation of glutamic plasminogen by tPA using 0.05 mol/l Tris buffer (pH 7.35) containing NaCl (0.9%)
-
plasminogen activator inhibitor-1
-
dose-dependently facilitates the dissociation of membrane-retained tPA and increases the amounts of tPA-plasminogen activator inhibitor-1 high-molecular-weight complexes in the medium
Polymerized fibrin
-
enhances amidolytic activity of both one-chain tPA forms but not of two-chain tPA
-
rolipram
-
increases tPA activity in lipopolysaccharide-stimulated rat primary astrocytes
statins
-
can induce tPA and inhibits plasminogen activator inhibitor-1
-
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0004 - 0.39
(p-F)-FPRANSNH-C2H5
0.86
Asp-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
2.3
benzyloxycarbonyl-Asp(O-tert-butyl)-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.72
benzyloxycarbonyl-Asp-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.52
benzyloxycarbonyl-D-Arg-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
1.8
benzyloxycarbonyl-D-Asp(O-tert-butyl)-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
1.2
benzyloxycarbonyl-D-Glu(O-tetr-butyl)-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
2.6
benzyloxycarbonyl-D-Glu-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.3
benzyloxycarbonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.9
benzyloxycarbonyl-Glu-(O-tert-butyl)Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
2.2
benzyloxycarbonyl-Glu-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
1.36
benzyloxycarbonyl-Val-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.0004 - 0.071
Boc-(p-F)-FPRANSNH-C2H5
0.013 - 0.03
Boc-D-FLRANSNH-C3H7
0.0008
Boc-D-FLRANSNHC3H7
-
pH 7.4, 25°C, ratio tc/sc
0.0026 - 0.047
Boc-D-FPRANSNH-C6H11
0.0027 - 0.091
Boc-D-FVRANSNH-C2H5
0.0004 - 0.023
Boc-D-LGRANSNH-C6H11
0.0006 - 0.066
Boc-D-LPRANSNH-C3H7
0.0006 - 0.36
Boc-D-LSRANSNH-C3H7
0.0007 - 0.14
Boc-D-VGRANSNH-C4H9
0.0005
Boc-D-VPR-ANSNHC4H9
-
pH 7.4, 25°C, ratio tc/sc
0.015 - 0.029
Boc-D-VPRANSNH-C4H9
0.1
Boc-L-VGRANSNHC4H9
-
pH 7.4, 25°C
5.32
cyclohexylglycyl-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
1.7
D-Asp(O-tert-butyl)-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
1.53
D-cyclohexylglycyl-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.0074 - 0.01
D-FLRANSNH-C3H7
0.00078
D-FPR-ANSNH-C2H4OCH3
-
pH 7.4, 25°C, ratio tc/sc
0.00046
D-FPR-ANSNH-CH2COOCH3
-
pH 7.4, 25°C, ratio tc/sc
0.099
D-FPR-ANSNH-n-C6H13
-
pH 7.4, 25°C, sc-tPA
0.00038 - 0.25
D-FPRANSN-(CH2)6
0.00037 - 0.32
D-FPRANSN-C2H5-C2H5
0.00059 - 0.15
D-FPRANSNH-c-C6H11
0.14 - 0.18
D-FPRANSNH-C2H4OCH3
0.0057 - 0.077
D-FPRANSNH-C6H11
0.0004 - 0.063
D-FPRANSNH-C6H5CH2
0.029 - 0.063
D-FPRANSNH-CH2COOCH3
0.00022 - 0.33
D-FPRANSNH-i-C3H7
0.0004 - 0.12
D-FPRANSNH-n-C4H9
0.095 - 0.096
D-FPRANSNH-n-C6H13
0.0011 - 0.084
D-FPRANSNH-t-C4H9
0.0011 - 0.016
D-FVRANSNH-C2H5
2.9
D-Glu-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.83
D-hexahydrotyrosyl-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.000086 - 0.694
D-Ile-Pro-Arg-p-nitroanilide
0.001 - 0.041
D-LGRANSNH-C6H11
0.0003 - 0.098
D-LPRANSNH-C3H7
0.0012 - 0.069
D-LSRANSNH-C3H7
2.1
D-Lys-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.7
D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.0015 - 0.058
D-VGRANSNH-C4H9
0.0003 - 0.11
D-VPRANSNH-C4H9
3.2
Glu-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.00002 - 0.065
Glu-plasminogen
-
0.036 - 0.97
L-FPRANSNH-C2H5
0.46
L-VGRANSNH-C4H9
-
pH 7.4, 25°C
5.9
Lys-Lys-Cys-Pro-Gly-Arg-Val-Val-Gly-Gly-Cys-Val-Ala-His
-
-
3.6
Lys-Lys-Ser-Pro-Gly-Arg-Val-Val-Gly-Gly-Ser-Val-Ala-His
-
-
0.00001 - 0.019
Lys-plasminogen
-
0.34
methyloxycarbonyl-D-cyclohexylalanyl-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.42
methyloxycarbonyl-D-cyclohexylglycyl-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.39
methyloxycarbonyl-D-hexahydrotyrosyl-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.62
methyloxycarbonyl-D-Leu-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.99
methyloxycarbonyl-D-Nle-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.8
methyloxycarbonyl-D-Val-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.1
methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.000017
Peptide S-2288
-
-
3.15
pGlu-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
2
Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
0.000018 - 0.065
plasminogen
-
3.5 - 4.1
S-2288TM
-
0.14
SNase PFGRSA
-
pH 7.4, 37°C
-
0.079
SNase PFGRSAG
-
pH 7.4, 37°C
-
0.0099
SNase PGPFGRSAG
-
pH 7.4, 37°C
-
0.0093
SNase PGPFGRSAGG
-
pH 7.4, 37°C
-
0.017
SNase PGSGRSAG
-
pH 7.4, 37°C
-
0.018
SNase PHYGRSGG
-
pH 7.4, 37°C
-
0.0099
SNase PPFGRSAG
-
pH 7.4, 37°C
-
0.0089
SNase PQRGRSAG
-
pH 7.4, 37°C
-
0.4 - 4.6
spectrozyme tPA
3.5
tert-butoxycarbonyl-Gly-Gly-Arg-p-nitroanilide
-
pH 8.0, 25°C
additional information
additional information
-
Km values of different glycoforms of plasminogen by tPA variants
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.099 - 6.08
(p-F)-FPRANSNH-C2H5
0.11 - 6.08
Boc-(p-F)-FPRANSNH-C2H5
0.01 - 4.7
Boc-D-FLRANSNH-C3H7
0.017 - 0.15
Boc-D-FPRANSNH-C6H11
7.9
Boc-D-FVR-ANSNH-C2H5
Homo sapiens
-
pH 7.4, 25°C, ratio tc/sc
0.019 - 0.49
Boc-D-FVRANSNH-C2H5
0.012 - 3.3
Boc-D-LGRANSNH-C6H11
0.038 - 6.08
Boc-D-LPRANSNH-C3H7
0.022 - 6.08
Boc-D-LSRANSNH-C3H7
0.036 - 5
Boc-D-VGRANSNH-C4H9
0.065 - 3.8
Boc-D-VPRANSNH-C4H9
0.084
Boc-L-VGRANSNHC4H9
Homo sapiens
-
pH 7.4, 25°C
0.018
D-FLRANSNH-C3H7
Homo sapiens
-
pH 7.4, 25°C, tc-tPA
0.016
D-FPR-ANSNH-C6H11
Homo sapiens
-
pH 7.4, 25°C, sc-tPA
0.45
D-FPR-ANSNH-C6H5CH2
Homo sapiens
-
pH 7.4, 25°C, sc-tPA
0.47
D-FPR-ANSNH-n-C4H9
Homo sapiens
-
pH 7.4, 25°C, tc-tPA
3.3 - 3.6
D-FPR-ANSNH-n-C6H13
3.8
D-FPR-ANSNH-t-C4H9
Homo sapiens
-
pH 7.4, 25°C, ratio tc/sc
0.51 - 6.08
D-FPR-ANSNHC6H11
0.13 - 1.7
D-FPRANSN-(CH2)6
0.09 - 1.6
D-FPRANSN-C2H5-C2H5
0.15
D-FPRANSN-H-c-C6H11
Homo sapiens
-
pH 7.4, 25°C, sc-tPA
0.2
D-FPRANSN-H-i-C3H7
Homo sapiens
-
pH 7.4, 25°C, tc-tPA
0.25 - 6.08
D-FPRANSN-H-t-C4H9
0.32 - 2.1
D-FPRANSNH-c-C6H11
0.27 - 6.08
D-FPRANSNH-C2H4OCH3
32
D-FPRANSNH-C6H11
Homo sapiens
-
pH 7.4, 25°C, ratio tc/sc
0.54 - 6.08
D-FPRANSNH-C6H5CH2
0.083 - 1.8
D-FPRANSNH-CH2COOCH3
0.29 - 6.08
D-FPRANSNH-i-C3H7
0.33 - 1.4
D-FPRANSNH-n-C4H9
1.1
D-FPRANSNH-n-C6H13
Homo sapiens
-
pH 7.4, 25°C, sc-tPA
0.025
D-FVR-ANSNH-C2H5
Homo sapiens
-
pH 7.4, 25°C, tc-tPA
0.011 - 2.3
D-FVRANSNH-C2H5
0.026 - 10.7
D-Ile-Pro-Arg-p-nitroanilide
0.034 - 4
D-LGR-ANSNH-C6H11
0.0084 - 0.057
D-LGRANSNH-C6H11
0.061 - 2.8
D-LPRANSNH-C3H7
0.019 - 5.3
D-LSRANSNH-C3H7
89
D-LSRANSNHC3H7
Homo sapiens
-
pH 7.4, 25°C
0.021 - 9
D-VGRANSNH-C4H9
0.059 - 2.7
D-VPRANSNH-C4H9
0.04
L-FPRANSNH-C2H5
Homo sapiens
-
pH 7.4, 25°C
0.08
L-VGRANSNH-C4H9
Homo sapiens
-
pH 7.4, 25°C
0.009
Lys-Lys-Cys-Pro-Gly-Arg-Val-Val-Gly-Gly-Cys-Val-Ala-His
Homo sapiens
-
-
0.0012
Lys-Lys-Ser-Pro-Gly-Arg-Val-Val-Gly-Gly-Ser-Val-Ala-His
Homo sapiens
-
-
0.0005 - 0.21
Lys-plasminogen
-
0.0025 - 0.4718
plasminogen
-
0.0041
SNase PFGRSA
Homo sapiens
-
pH 7.4, 37°C
-
0.018
SNase PFGRSAG
Homo sapiens
-
pH 7.4, 37°C
-
0.0075
SNase PGPFGRSAG
Homo sapiens
-
pH 7.4, 37°C
-
0.01
SNase PGPFGRSAGG
Homo sapiens
-
pH 7.4, 37°C
-
0.012
SNase PHYGRSGG
Homo sapiens
-
pH 7.4, 37°C
-
0.011
SNase PPFGRSAG
Homo sapiens
-
pH 7.4, 37°C
-
0.006
SNase PQRGRSAG
Homo sapiens
-
pH 7.4, 37°C
-
2 - 60
spectrozyme tPA
additional information
additional information
Homo sapiens
-
-
-
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000035
2,7-bis-(4-amidinobenzylidene)-cycloheptanone-(1)dihydrochloride
0.0318
6-carbamimidoyl-N-phenyl-2-naphthamide
-
pH 7.4-8.3, 37°C
0.0049
ethyl 4-(3-carbamimidoyl-N-[[2,4,6-tri(propan-2-yl)phenyl]sulfonyl]-L-phenylalanyl)piperazine-1-carboxylate
-
pH 7.4-8.3, 37°C
0.0584
N-(4-(aminomethyl)phenyl)-6-carbamimidoyl-2-naphthamide trifluoro acetate
-
pH 7.4-8.3, 37°C
0.0074
N-(benzylsulfonyl)-D-seryl-N-(4-carbamimidoylbenzyl)-L-alaninamide
-
pH 7.4-8.3, 37°C
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0039
2-([6-[(3'-carbamimidoylbiphenyl-3-yl)oxy]-3,5-difluoro-4-methylpyridin-2-yl]oxy)-4-(dimethylamino)benzoic acid
Homo sapiens
-
pH 7.4-8.3, 37°C
0.022
2-[(6-[[3'-(aminomethyl)biphenyl-3-yl]oxy]-3,5-difluoropyridin-2-yl)oxy]-4-methylbenzoic acid
Homo sapiens
-
pH 7.4-8.3, 37°C
0.03
2-[(6-[[5-amino-3'-(aminomethyl)biphenyl-3-yl]oxy]-3,5-difluoropyridin-2-yl)oxy]-4-methylbenzoic acid
Homo sapiens
-
pH 7.4-8.3, 37°C
0.0036
4-(2-aminoethoxy)-N-[3-chloro-2-ethoxy-5-(piperidin-1-yl)phenyl]-3,5-dimethylbenzamide
Homo sapiens
-
pH 7.4-8.3, 37°C
0.1
4-[(E)-(5-oxo-2-phenyl-1,3-oxazol-4(5H)-ylidene)methyl]benzenecarboximidamide
Homo sapiens
-
pH 7.4-8.3, 37°C
0.062
6-carbamimidoyl-N-(3,5-dimethoxyphenyl)-2-naphthamide
Homo sapiens
-
pH 7.4-8.3, 37°C
0.125
6-carbamimidoyl-N-phenyl-2-naphthamide
Homo sapiens
-
pH 7.4-8.3, 37°C
0.0053
6-methoxy-N-(3'-(trifluoromethyl)biphenyl-4-yl)-2-naphthamide
Homo sapiens
-
pH 7.4-8.3, 37°C
0.013
6-methoxy-N-(3'-(trifluoromethyl)biphenyl-4-yl)naphthalene-2-sulfonamide
Homo sapiens
-
pH 7.4-8.3, 37°C
0.021
6-methoxy-N-(3'-methoxybiphenyl-4-yl)-2-naphthamide
Homo sapiens
-
pH 7.4-8.3, 37°C
0.0086
6-methoxy-N-(3'-nitrobiphenyl-4-yl)-2-naphthamide
Homo sapiens
-
pH 7.4-8.3, 37°C
0.0061
bis[(phenylamino)acetyl] [2-(4-carbamimidamidophenyl)-1-[(methoxycarbonyl)amino]ethyl]phosphonate
Homo sapiens
-
pH 7.4-8.3, 37°C
0.023
diphenyl [2-(4-carbamimidamidophenyl)-1-[(methoxycarbonyl)amino]ethyl]phosphonate
Homo sapiens
-
pH 7.4-8.3, 37°C
0.011
methyl 4'-(6-carbamoyl-2-naphthamido)biphenyl-3-carboxylate
Homo sapiens
-
pH 7.4-8.3, 37°C
0.0084
methyl 4'-(6-methoxy-2-naphthamido)biphenyl-3-carboxylate
Homo sapiens
-
pH 7.4-8.3, 37°C
0.026
methyl 4'-(6-methoxynaphthalene-2-sulfonamido)biphenyl-3-carboxylate
Homo sapiens
-
pH 7.4-8.3, 37°C
0.062
N-(4-(aminomethyl)phenyl)-6-carbamimidoyl-2-naphthamide trifluoro acetate
Homo sapiens
-
pH 7.4-8.3, 37°C
0.0097
N2-(2,4'-dimethoxybiphenyl-4-yl)naphthalene-2,6-dicarboxamide
Homo sapiens
-
pH 7.4-8.3, 37°C
0.0034
N2-(3'-(trifluoromethyl)biphenyl-4-yl)naphthalene-2,6-dicarboxamide
Homo sapiens
-
pH 7.4-8.3, 37°C
0.0057
N2-(3'-methoxybiphenyl-4-yl)naphthalene-2,6-dicarboxamide
Homo sapiens
-
pH 7.4-8.3, 37°C
additional information
xenon
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.297
-
-
7.4
-
purified recombinant truncated enzyme, pH 8.3, 37°C
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.4 - 8.3
-
assay at, dependent on the substrate
7.5
-
assay at
7.8
-
assay at
8
-
assay at
8.3
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7 - 10
-
7: about 85% of activity maximum, 10: about 80% of activity maximum
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
primary astroglial cultures prepared from newborn rat cerebral cortices
Manually annotated by BRENDA team
-
transformed, carcinoma
Manually annotated by BRENDA team
-
in vitro model of the blood-brain barrier, primary rat astrocyte-enriched cultures are co-cultured with primary adult rat brain microvascular endothelial cells on opposite sides of a transwell membrane
Manually annotated by BRENDA team
-
vascular endothelial cell line producing GFP-tagged tPA
Manually annotated by BRENDA team
-
mouse endothelial cell line EOMA
Manually annotated by BRENDA team
-
transformed cell line
Manually annotated by BRENDA team